Lv11
46 积分 2025-02-28 加入
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
2小时前
已完结
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database
2小时前
已完结
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue
2小时前
已完结
Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study
2小时前
已完结
Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors
3小时前
已完结
[Chinese expert consensus on the clinical diagnosis and treatment of advanced breast carcinoma(2018)]
12天前
已完结
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
12天前
已完结
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
19天前
已完结
Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors
19天前
已完结
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer
24天前
已完结
皖公网安备34019202002308
